Table 1.
Summary of the cohort studied
| JAK2V617F and CALR mutation status | Total | ||||
|---|---|---|---|---|---|
| Subtype | JAK2V617F+ | CALRMut | JAK2V617F−/CALRWT | Unknown | |
| Controls | – | – | 15 | – | 15 |
| PV | 20 | – | – | – | 20 |
| ET | 26 | 9 | 6 | 31 | 72 |
| MF* | 18 | 14 | 5 | 16 | 53 |
| Total | 64 | 23 | 26 | 47 | 160 |
JAK2V617F and CALR lesions did not coexist (ie, JAK2V617F+ and CALRMut were mutually exclusive). All CALR mutations represent frameshift lesions in exon 9 of CALR.
*Includes both primary MF and ET/PV cases having undergone fibrotic transformation.
CALR, calreticulin; ET, essential thrombocythaemia; JAK2, Janus activated kinase 2; MF, myelofibrosis; Mut, mutated; PV, polycythaemia vera; WT, wild type.